Talk:Cabergoline: Difference between revisions

>Dextromethorphan
wording
>Blackhole
added summary sheet and substance box, removed picture
 
(3 intermediate revisions by 3 users not shown)
Line 1: Line 1:
{{headerpanel|{{Stub}}}}
{{headerpanel|{{Stub}}}}
[[File:Cabergoline.svg|300px|thumbnail|The structure of cabergoline]]
{{SummarySheet}}
'''Cabergoline''' is a chemical of the [[lysergamide]] and ergopeptine classes. It is a close derivative of [[LSD]], or more specifically, [[AL-LAD]], but instead shares many effects with related, non-psychedelic medicinal compounds such as [[ergotamine]], ergonovine or [[lisuride]]. It is occasionally prescribed to treat symptoms of high prolactin levels and managing Parkinson's disease.
{{SubstanceBox/Cabergoline}}
'''Cabergoline''' is a chemical of the [[lysergamide]] and ergopeptine classes. It is a close derivative of [[LSD]], more specifically, [[AL-LAD]], but instead shares many effects with related, non-psychedelic medicinal compounds such as [[ergotamine]], ergonovine or [[lisuride]]. It is occasionally prescribed to treat symptoms of high prolactin levels and managing Parkinson's disease.


Cabergoline is not predominantly psychedelic, it mainly exerts its effects at the [[dopamine]] D<sub>2</sub> receptor as an agonist but has comparatively little effect on the [[serotonin]] 5-HT<sub>2A</sub> receptor where it acts as a partial agonist.
Cabergoline is not predominantly psychedelic, it mainly exerts its effects at the [[dopamine]] D<sub>2</sub> receptor as an agonist but has comparatively little effect on the [[serotonin]] 5-HT<sub>2A</sub> receptor where it acts as a partial agonist.


Cabergoline has little recreational value other than its unique property of reducing or eliminating the male refractory period, thereby allowing men to experience multiple ejaculatory orgasms in rapid succession.<ref>Krüger TH, Haake P, Haverkamp J, et al. (December 2003). "Effects of acute prolactin manipulation on sexual drive and function in males". Journal of Endocrinology. 179 (3): 357–65. CiteSeerX 10.1.1.484.4005. doi:10.1677/joe.0.1790357. PMID 14656205.</ref><ref>Hollander, Adam B.; Pastuszak, Alexander W.; Lipshultz, Larry I. (2016). "Cabergoline in the Treatment of Male Orgasmic Disorder—A Retrospective Pilot Analysis". Journal of Sexual Medicine. 4 (4): e28–e33. doi:10.1016/j.esxm.2015.09.001. PMC 4822480. PMID 26944776.</ref>
Cabergoline has little recreational value other than its unique property of reducing or eliminating the male refractory period, allowing men to experience multiple ejaculatory orgasms in rapid succession.<ref>{{cite journal | vauthors=((Krüger, T. H. C.)), ((Haake, P.)), ((Haverkamp, J.)), ((Krämer, M.)), ((Exton, M. S.)), ((Saller, B.)), ((Leygraf, N.)), ((Hartmann, U.)), ((Schedlowski, M.)) | journal=The Journal of Endocrinology | title=Effects of acute prolactin manipulation on sexual drive and function in males | volume=179 | issue=3 | pages=357–365 | date= December 2003 | issn=0022-0795 | doi=10.1677/joe.0.1790357}}</ref><ref>{{cite journal | vauthors=((Hollander, A. B.)), ((Pastuszak, A. W.)), ((Hsieh, T.-C.)), ((Johnson, W. G.)), ((Scovell, J. M.)), ((Mai, C. K.)), ((Lipshultz, L. I.)) | journal=Sexual Medicine | title=Cabergoline in the Treatment of Male Orgasmic Disorder-A Retrospective Pilot Analysis | volume=4 | issue=1 | pages=e28-33 | date= March 2016 | issn=2050-1161 | doi=10.1016/j.esxm.2015.09.001}}</ref>


==See also==
==See also==
Return to "Cabergoline" page.